The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Mar 2021 14:31

IN BRIEF: Open Orphan wins new contract with Oxford BioTherapeutics

IN BRIEF: Open Orphan wins new contract with Oxford BioTherapeutics

Read more
9 Mar 2021 11:38

Open Orphan subsidiary awarded contract with Oxford BioTherapeutics

(Sharecast News) - Specialist pharmaceuticals contract research organisation Open Orphan announced on Tuesday that its subsidiary Venn Life Sciences had been awarded a contract for a study with clinical-stage oncology company Oxford BioTherapeutics.

Read more
17 Feb 2021 13:48

IN BRIEF: Open Orphan Covid Characterisation Study Gets Approval

IN BRIEF: Open Orphan Covid Characterisation Study Gets Approval

Read more
3 Feb 2021 16:28

Open Orphan opens new quarantine clinic in Whitechapel

(Sharecast News) - Pharmaceutical services contract research organisation (CRO) Open Orphan has opened a new quarantine clinic in east London, it announced on Wednesday.

Read more
3 Feb 2021 11:55

IN BRIEF: Open Orphan Launches New Quarantine Clinic In London

IN BRIEF: Open Orphan Launches New Quarantine Clinic In London

Read more
1 Feb 2021 13:20

Open Orphan renews contract with Carna Biosciences

(Sharecast News) - Pharmaceutical services clinical research organisation Open Orphan announced a further contract renewal with Carna Biosciences on Monday, extending its integrated drug development consultancy services with Open Orphan subsidiary Venn Life Sciences.

Read more
1 Feb 2021 11:54

IN BRIEF: Open Orphan Inks Contract Renewal With Carna Biosciences

IN BRIEF: Open Orphan Inks Contract Renewal With Carna Biosciences

Read more
20 Jan 2021 21:16

IN BRIEF: Open Orphan Opens Two New Volunteer Recruitment Centres

IN BRIEF: Open Orphan Opens Two New Volunteer Recruitment Centres

Read more
11 Jan 2021 15:56

Open Orphan confirms first volunteer dosing of needle-free Covid vaccine

(Sharecast News) - Specialist pharmaceutical services contract research organisation Open Orphan announced on Monday that the first volunteer had been dosed with the Codagenix needle-free intranasal Covid-19 vaccine, 'COVI-VAC'.

Read more
11 Jan 2021 11:45

Open Orphan Doses First Volunteer In Needle Free Covid Vaccine Trial

Open Orphan Doses First Volunteer In Needle Free Covid Vaccine Trial

Read more
6 Jan 2021 14:37

IN BRIEF: Open Orphan Inks Contract Renewal With Top-3 Pharma Client

IN BRIEF: Open Orphan Inks Contract Renewal With Top-3 Pharma Client

Read more
23 Dec 2020 19:50

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

Read more
22 Dec 2020 14:26

IN BRIEF: Open Orphan Pens Contract Extension With Major Client

IN BRIEF: Open Orphan Pens Contract Extension With Major Client

Read more
22 Dec 2020 10:44

Open Orphan renews contract with top-3 pharma client

(Sharecast News) - Pharmaceutical services contract research organisation Open Orphan announced a contract renewal on Tuesday, extending its consultancy services with an unnamed "major top-three global" pharmaceutical client to December 2021.

Read more
14 Dec 2020 22:04

UK TRADING UPDATE SUMMARY: Novacyt Unveils New Test For Mink Covid

UK TRADING UPDATE SUMMARY: Novacyt Unveils New Test For Mink Covid

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.